BioReliance (Merck) vs Charles River Laboratories: CDMO Comparison

How does BioReliance (Merck) compare to Charles River Laboratories?

As of Jun 2026, BioReliance (Merck): 6 FDA inspections (including 2 NAI, 4 VAI and 0 OAI), 10 EMA/MHRA GMP certificates. Signal Score 80.3. Charles River Laboratories: 9 FDA inspections (including 6 NAI, 3 VAI and 0 OAI), 11 EMA/MHRA GMP certificates. Signal Score 86.3. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of BioReliance (Merck) and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Glasgow, UK · Rockville, MD
Signal Score
80/100
Quality (FDA + GMP)
97/100
FDA inspections
6
— NAI / VAI / OAI
2 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
10
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Biologics
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score
86/100
Quality (FDA + GMP)
99/100
FDA inspections
9
— NAI / VAI / OAI
6 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
9
MHRA GMP certificates (compliant)
2
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Charles River Laboratories holds 9 active EMA GMP certificates; BioReliance (Merck) does not appear in EudraGMDP.
  • BioReliance (Merck) has stronger MHRA / UK coverage (10 compliant certificates vs 2).

Across the cross-modality scorecard, Charles River Laboratories carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: BioReliance (Merck) vs Charles River Laboratories

How does BioReliance (Merck) compare to Charles River Laboratories?

On CDMO Signal's composite Signal Score, BioReliance (Merck) is 80/100 and Charles River Laboratories is 86/100; BioReliance (Merck) has 6 FDA inspections on record vs 9 for Charles River Laboratories; European coverage is 10 active EMA+MHRA certificates for BioReliance (Merck) vs 11 for Charles River Laboratories. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, BioReliance (Merck) or Charles River Laboratories?

Both BioReliance (Merck) and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioReliance (Merck) has 6 FDA inspections on record; Charles River Laboratories has 9.

How do BioReliance (Merck) and Charles River Laboratories compare on European GMP coverage?

BioReliance (Merck) holds 0 active EMA GMP certificates and 10 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

BioReliance (Merck) carries a Signal Score of 80/100 and Charles River Laboratories carries 86/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating BioReliance (Merck) and Charles River Laboratories for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.